• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cancer medications approved by FDA accelerated approval program struggle to show benefit

byAnees DaudandJames England
May 30, 2019
in Chronic Disease, Oncology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this updated review of cancer medications that received Food and Drug Administration (FDA) accelerated approval program, only 20% of drugs demonstrate improved overall survival benefit.

2. Final FDA approval was commonly made based on surrogate measures. A substantial proportional of confirmatory trials are still ongoing or delayed despite initial approval.

Evidence Rating Level: 2 (Good)          

Study Rundown: The FDA accelerated approval program for cancer therapies was developed in an effort to improve access to therapy for life-threatening conditions. The program was started in 1992 and provides conditional approval for agents based on trials with surrogate endpoints with a requirement for subsequent confirmatory studies with clinically meaningful endpoints so that patients and healthcare providers will be able to make decisions knowing the risks and benefits of these novel therapies. The current study is an updated review of cancer medications that have received approval though the accelerated program. The study found that only 20% of medications show improvement in overall survival. Many follow up trials and final approvals were based on surrogate measures.

The main strength of the study is the thorough review of all cancer drugs approved through this FDA program. The limitations of the study include the cutoff only looking into approvals to the end of the 2017 study period, with many updates now available. This study also did not review trial methodology for the medications receiving approval.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval

RELATED REPORTS

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

Wellness Check: Mental Health

In-Depth [systematic review]: This study was a systematic review of literature on endpoints used in preaffirmatory and confirmatory trials for cancer medications receiving FDA accelerated approval. Outcomes for confirmatory trials were grouped into those that improved overall survival or quality of life, surrogate measures used in the preaffirmatory trial, and surrogate measures different from the preaffirmatory trial. Trials were included to have surrogate measures if the primary outcome was: event-free survival, major hematologic response, durable complete remission rate, major hematologic response and cytogenic response, minimal residual disease response rate, durable objective overall response rate, progression/disease-free survival, pathological complete response, and metastasis-free survival.

From 1992 to the end of the study period May 31, 2017 the FDA gave accelerated approval to 93 cancer drugs. A total of 51 of these medications had subsequent approval based on confirmatory trials. For medications awaiting final approval, 5 had delayed confirmatory trials, 10 trials were still pending, 9 trials were still ongoing. For 19 (20%) of approved medications there were confirmatory trials demonstrating improved overall survival, while 19 (20%) trials reported the same surrogate endpoints, and 20 (21%) had trials with different surrogate endpoints.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Quick Take: Liver Fibrosis and Metabolic Alterations in Adults with Alpha1 Antitrypsin Deficiency Caused by the Pi*ZZ Mutation

Next Post

Laparoscopic distal gastrectomy non-inferior to open distal gastrectomy for locally advanced gastric cancer

RelatedReports

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
StudyGraphics

#VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma

May 20, 2022
Exercise intervention linked to reduced functional decline among elderly patients admitted to the hospital
Wellness

Virtual yoga and meditation intervention may be associated with increased health-related quality of life

May 20, 2022
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women
Wellness

Wellness Check: Mental Health

May 19, 2022
#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Next Post
Quick Take: Combined Surgery and Extensive Intraoperative Peritoneal Lavage vs Surgery Alone for Treatment of Locally Advanced Gastric Cancer: The SEIPLUS Randomized Clinical Tria

Laparoscopic distal gastrectomy non-inferior to open distal gastrectomy for locally advanced gastric cancer

Quick Take: Robot assisted training for the upper limb after stroke (RATULS)

Quick Take: Robot assisted training for the upper limb after stroke (RATULS)

Age and breast cancer risk factors associated with false-positive mammography results

Quick Take: Genomic characterization of metastatic breast cancers

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.